PMMA particle-mediated DNA vaccine for cervical cancer

Journal of Biomedical Materials Research - Part A

Volumn 88, Issue 4, 2009, Pages 849-857

  Lou, Pei Jen ^a   Cheng, Wen Fang ^b   Chung, Yi Chen ^c   Cheng, Che Yuan ^b   Chiu, Lien Hua ^d   Young, Tai Horng ^b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIWAN TEXTILE RESEARCH INSTITUTE   (Taiwan)

Author keywords

Cervical cancer; DNA vaccine; Gene gun; Poly(methyl methacrylate) (PMMA) particles

Indexed keywords

ANTI TUMORS; CERVICAL CANCER; CLINICAL APPLICATIONS; DNA VACCINATIONS; DNA VACCINE; FOOD AND DRUG ADMINISTRATIONS; GENE GUN; IMMUNE RESPONSE; IMMUNOGENICITY; IN-VITRO; IN-VIVO; INFLAMMATORY CYTOKINES; PMMA PARTICLES; POLY(METHYL METHACRYLATE) (PMMA) PARTICLES; POLYMER PARTICLES; SYNTHETIC POLYMERS;

BONE CEMENT; CHARGED PARTICLES; DNA; ELECTRON GUNS; ESTERS; GENES; NUCLEIC ACIDS; ORGANIC ACIDS; PARTICLE SIZE; POLYMERS; SURFACE CHARGE;

VACCINES;

BONE CEMENT; CYTOKINE; DNA VACCINE; PLASMID DNA; POLY(METHYL METHACRYLATE); POLYMER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; GENE GUN; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PHAGOCYTOSIS; SURFACE CHARGE; SYNTHESIS; UTERINE CERVIX CANCER;

ANIMALS; CELL LINE; DNA; FEMALE; HUMANS; MACROPHAGES; MATERIALS TESTING; MICE; PARTICLE SIZE; PLASMIDS; POLYMETHYL METHACRYLATE; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 60349128014     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31919     Document Type: Article

References (31)

1. Berzofsky JA, Terabe M, Oh SK, Belyakov IM, Ahlers JD, Janik JE, Morris JC. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004;113:1515-1525.
2. Weiner DB, Kennedy RC. Genetic vaccines. Sci Am 1999; 281:50-57.
3. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-648.
4. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: Immunology, application, and optimization. Annu Rev Immunol 2000;18:927-974.
5. Dean HJ, Haynes J, Schmaljohn C. The role of particle-mediated DNA vaccines in biodefense preparedness. Adv Drug Deliv Rev 2005;57:1315-1342.
6. Maloney WJ, Smith RL, Schmalzried TP, Chiba J, Huene D, Rubash H. Isolation and characterization of wear particles generated in patients who have had failure of a hip arthroplasty without cement. J Bone Joint Surg Am 1995;77:1301-1310.
7. Gelb H, Schumacher HR, Cuckler J, Ducheyne P, Baker DG. In vivo inflammatory response to polymethylmethacrylate particulate debris: Effect of size, morphology and surface area. J Orthop Res 1994;12:83-92.
8. Gonzalez O, Smith RL, Goodman SB. Effect of size, concentration, surface area, and volume of Polymethylmethacrylate particles on human macrophages in vitro. J Biomed Meter Res 1996;30:463-473.
9. Prabhu A, Shelburne CE, Gibbons DF. Cellular proliferation and cytokine responses of murine macrophage cell line J774A.1 to polymethylmethacrylate and cobalt-chrome alloy particles. J Biomed Mater Res 1998;42:655-663.
10. Lohmann CH, Dean DD, Köster G, Casasola D, Buchhorn GH, Fink U, Schwartz Z, Boyan BD. Ceramic and PMMA particles differentially affect osteoblast phenotype. Biomaterials 2002;23:1855-1863.
11. Haynes DR, Hay SJ, Rogers SD, Ohta S, Howie DW, Graves SH. Regulation of bone cells by particle-activated mononuclear phagocytes. J Bone Joint Surg Br 1997;79:988-994.
12. Haynes DR, Rogers SD, Hay S, Pearcy MJ, Howie DW. The differences in toxicity and release of bone-resorbing mediators induced by titanium and cobalt-chromium-alloy wear particles. J Bone Joint Surg Am 1993;75:825-834.
13. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003;14:709-714.
14. Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 2005;28:382-388.
15. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001;166:6218-6226.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application of proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
17. Kusumawati A, Commes T, Liautard JP, Widada JS. Transfection of myelomonocytic cell lines, cellular response to a lipid-based reagent and electroporation. Anal Biochem 1999;269, 219-221.
18. Arkusz J, Stepnik M, Trzaska D, Dastych J, Rydzynski K. Assessment of usefulness of J774A.1 macrophages for the assay of IL-1b promoter activity. Toxicol In Vitro 2006;20:109-116.
19. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004;114:1241-1244.
20. Condon C, Watkins SC, Celluzi CM, Thompson K, Falo LD. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996;2:1122-1128.
21. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998;188:1075-1082.
22. Castaldello A, Brocca-Cofano E, Voltan R, Triulzi C, Altavilla G, Laus M, Sparnacci K, Ballestri M, Tondelli L, Fortini C, Gavioli R, Ensoli B, Caputo A. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 Tat DNA vaccination. Vaccine 2006;24:5655-5669.
23. Caputo A, Brocca-Cofano E, Castaldello A, De Michele R, Altavilla G, Marchisio M, Gavioli R, Rolen U, Chiarantini L, Cerasi A, Dominici S, Magnani M, Cafaro A, Sparnacci K, Laus M, Tondelli L, Ensoli B. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine 2004;22:2910-2924.
24. Shephard MJ, Todd D, Adair BM, Po AL, Mackie DP, Scott EM. Immunogenicity of bovine parainfluenza type 3 virus proteins encapsulated in nanoparticle vaccines, following intranasal administration to mice. Res Vet Sci 2003;74:187-190.
25. Kreuter J. Nanoparticles as adjuvants for vaccines. Pharm Biotechnol 1995;6:463-472.
26. Stieneker F, Lower J, Kreuter J. Different kinetics of the humoral immune response to inactivated HIV-1 and HIV-2 in mice: Modulation by PMMA nanoparticle adjuvant. Vaccine Res 1993;2:111-118.
27. Kreuter J. Physicochemical characterization of nanoparticles and their potential for vaccine preparation. Vaccine Res 1992;1:93-98.
28. Stieneker F, Kreuter J, Lower J. High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS 1991;5:431-435.
29. Sigal LH, Ron YR. Immunology and Inflammation: Basic Mechanism and Clinical Consequences. New York: McGraw-Hill; 1994.
30. Kitamura H, Kamon H, Sawa S, Park SJ, Katunuma N, Ishihara K, Murakami M, Hirano T. IL-6-STAT3 controls intracellular MHC class II alpha beta dimmer level through cathepsin S activity in dendritic cells. Immunity 2005;23:491-502.
31. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000;97:811-816.